 Jose Diaz-Miron
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intestine, Small | 8 | 2017 | 121 | 1.240 |
Why?
| | Surgeons | 5 | 2023 | 236 | 1.200 |
Why?
| | Central Venous Catheters | 1 | 2023 | 40 | 0.870 |
Why?
| | Catheter-Related Infections | 1 | 2023 | 61 | 0.850 |
Why?
| | Intestinal Atresia | 1 | 2023 | 15 | 0.840 |
Why?
| | Catheterization, Central Venous | 1 | 2023 | 83 | 0.820 |
Why?
| | Myofibromatosis | 1 | 2021 | 6 | 0.780 |
Why?
| | Adaptation, Physiological | 6 | 2017 | 484 | 0.700 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2023 | 285 | 0.640 |
Why?
| | Neovascularization, Physiologic | 3 | 2015 | 174 | 0.560 |
Why?
| | Short Bowel Syndrome | 5 | 2017 | 19 | 0.520 |
Why?
| | Lung Diseases | 1 | 2022 | 690 | 0.500 |
Why?
| | Wounds and Injuries | 1 | 2022 | 674 | 0.470 |
Why?
| | Coronary Aneurysm | 1 | 2014 | 11 | 0.460 |
Why?
| | Thoracic Injuries | 1 | 2014 | 54 | 0.440 |
Why?
| | Baseball | 1 | 2014 | 49 | 0.440 |
Why?
| | Telemedicine | 1 | 2021 | 662 | 0.430 |
Why?
| | Hemostasis | 1 | 2013 | 64 | 0.430 |
Why?
| | Hematopoiesis | 1 | 2013 | 170 | 0.410 |
Why?
| | Infant, Newborn | 3 | 2023 | 5038 | 0.400 |
Why?
| | Wounds, Nonpenetrating | 1 | 2014 | 249 | 0.370 |
Why?
| | Lung | 1 | 2022 | 3521 | 0.330 |
Why?
| | Intestinal Mucosa | 5 | 2017 | 532 | 0.310 |
Why?
| | Receptor, IGF Type 1 | 2 | 2017 | 58 | 0.260 |
Why?
| | Insulin-Like Growth Factor II | 2 | 2017 | 23 | 0.260 |
Why?
| | Retinoblastoma Protein | 2 | 2017 | 52 | 0.250 |
Why?
| | Child | 9 | 2023 | 18401 | 0.250 |
Why?
| | Chemokine CXCL5 | 2 | 2015 | 12 | 0.240 |
Why?
| | Pandemics | 2 | 2022 | 1310 | 0.220 |
Why?
| | Enoxaparin | 1 | 2023 | 52 | 0.210 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2023 | 18 | 0.210 |
Why?
| | Specialties, Surgical | 1 | 2023 | 67 | 0.200 |
Why?
| | False Positive Reactions | 1 | 2022 | 109 | 0.190 |
Why?
| | Scalp | 1 | 2021 | 29 | 0.190 |
Why?
| | Operating Rooms | 1 | 2022 | 85 | 0.190 |
Why?
| | Humans | 17 | 2023 | 114045 | 0.190 |
Why?
| | Photography | 1 | 2021 | 88 | 0.190 |
Why?
| | Intestinal Obstruction | 1 | 2021 | 39 | 0.180 |
Why?
| | Transgender Persons | 1 | 2023 | 134 | 0.180 |
Why?
| | Pregnancy Outcome | 1 | 2023 | 337 | 0.180 |
Why?
| | Prospective Studies | 2 | 2022 | 6195 | 0.180 |
Why?
| | Thrombosis | 1 | 2023 | 295 | 0.170 |
Why?
| | Retrospective Studies | 4 | 2023 | 12521 | 0.170 |
Why?
| | Trauma Centers | 1 | 2022 | 347 | 0.160 |
Why?
| | Neuroblastoma | 2 | 2011 | 133 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2022 | 735 | 0.160 |
Why?
| | Mice, Knockout | 5 | 2017 | 2562 | 0.160 |
Why?
| | Infant, Premature | 1 | 2021 | 478 | 0.150 |
Why?
| | Curriculum | 1 | 2023 | 813 | 0.150 |
Why?
| | Patient Satisfaction | 1 | 2021 | 571 | 0.150 |
Why?
| | Sensitivity and Specificity | 1 | 2022 | 1690 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 427 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2022 | 323 | 0.140 |
Why?
| | Mice, Inbred C57BL | 6 | 2015 | 4680 | 0.140 |
Why?
| | Incidence | 1 | 2023 | 2314 | 0.130 |
Why?
| | Decision Making | 1 | 2021 | 760 | 0.120 |
Why?
| | Caregivers | 1 | 2021 | 713 | 0.120 |
Why?
| | Intestinal Absorption | 1 | 2015 | 93 | 0.120 |
Why?
| | Enterocytes | 1 | 2014 | 14 | 0.120 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 91 | 0.110 |
Why?
| | Vitamin K Deficiency Bleeding | 1 | 2013 | 3 | 0.110 |
Why?
| | Extracorporeal Circulation | 1 | 2013 | 13 | 0.110 |
Why?
| | Dietary Proteins | 1 | 2014 | 121 | 0.110 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2013 | 29 | 0.110 |
Why?
| | Body Composition | 2 | 2014 | 590 | 0.110 |
Why?
| | Infant | 2 | 2023 | 7943 | 0.110 |
Why?
| | Intracranial Hemorrhages | 1 | 2013 | 76 | 0.110 |
Why?
| | Diet, High-Fat | 1 | 2014 | 225 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2272 | 0.100 |
Why?
| | ErbB Receptors | 1 | 2015 | 554 | 0.100 |
Why?
| | Weight Gain | 1 | 2014 | 453 | 0.090 |
Why?
| | Pregnancy | 1 | 2023 | 5499 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2011 | 55 | 0.090 |
Why?
| | Adolescent | 2 | 2021 | 17800 | 0.090 |
Why?
| | Imidazoles | 1 | 2011 | 203 | 0.090 |
Why?
| | Male | 7 | 2023 | 55396 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 314 | 0.090 |
Why?
| | Angiogenesis Inhibitors | 1 | 2011 | 213 | 0.080 |
Why?
| | Animals | 9 | 2017 | 31565 | 0.080 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 280 | 0.080 |
Why?
| | Piperazines | 1 | 2011 | 310 | 0.080 |
Why?
| | Bacteria | 1 | 2014 | 725 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 496 | 0.080 |
Why?
| | RNA | 1 | 2014 | 806 | 0.070 |
Why?
| | Enteral Nutrition | 2 | 2023 | 157 | 0.070 |
Why?
| | Microbiota | 1 | 2014 | 648 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 660 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2009 | 385 | 0.070 |
Why?
| | Mice | 7 | 2017 | 14843 | 0.070 |
Why?
| | Female | 5 | 2023 | 59324 | 0.060 |
Why?
| | Postoperative Period | 2 | 2017 | 288 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2014 | 3498 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2322 | 0.060 |
Why?
| | Random Allocation | 2 | 2014 | 328 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2009 | 1016 | 0.050 |
Why?
| | Gender Identity | 1 | 2023 | 100 | 0.050 |
Why?
| | Disposable Equipment | 1 | 2022 | 15 | 0.050 |
Why?
| | Heparin | 1 | 2023 | 225 | 0.050 |
Why?
| | Adenoidectomy | 1 | 2022 | 60 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2015 | 2173 | 0.050 |
Why?
| | Blood Coagulation | 1 | 2023 | 200 | 0.050 |
Why?
| | Hospital Costs | 1 | 2022 | 104 | 0.050 |
Why?
| | Adhesives | 1 | 2021 | 11 | 0.050 |
Why?
| | Tissue Adhesions | 1 | 2021 | 26 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4595 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2014 | 1624 | 0.040 |
Why?
| | Intestines | 1 | 2023 | 325 | 0.040 |
Why?
| | Hospitals, Pediatric | 1 | 2022 | 478 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2022 | 479 | 0.030 |
Why?
| | United States | 2 | 2023 | 12137 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2014 | 2550 | 0.030 |
Why?
| | Apoptosis | 2 | 2015 | 2349 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2021 | 970 | 0.030 |
Why?
| | Glucose Transporter Type 2 | 1 | 2014 | 10 | 0.030 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2014 | 10 | 0.030 |
Why?
| | Fish Oils | 1 | 2014 | 21 | 0.030 |
Why?
| | Tissue and Organ Harvesting | 1 | 2014 | 62 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2011 | 2700 | 0.030 |
Why?
| | Microcirculation | 1 | 2014 | 133 | 0.030 |
Why?
| | Tamoxifen | 1 | 2014 | 190 | 0.030 |
Why?
| | Colorado | 1 | 2023 | 4090 | 0.030 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2014 | 122 | 0.030 |
Why?
| | Linear Models | 1 | 2014 | 768 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1143 | 0.020 |
Why?
| | Energy Intake | 1 | 2014 | 427 | 0.020 |
Why?
| | Adult | 2 | 2023 | 30375 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 802 | 0.020 |
Why?
| | Bevacizumab | 1 | 2011 | 114 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 9049 | 0.020 |
Why?
| | Mice, Nude | 1 | 2011 | 628 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 250 | 0.020 |
Why?
| | Weight Loss | 1 | 2014 | 642 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2015 | 946 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 521 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 145 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2011 | 695 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 157 | 0.020 |
Why?
| | Down-Regulation | 1 | 2011 | 594 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 164 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2011 | 445 | 0.020 |
Why?
| | Transfection | 1 | 2009 | 863 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3397 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2014 | 4392 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2011 | 1145 | 0.020 |
Why?
| | Computational Biology | 1 | 2009 | 528 | 0.020 |
Why?
| | Base Sequence | 1 | 2009 | 2114 | 0.020 |
Why?
| | Phosphorylation | 1 | 2009 | 1558 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2783 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2014 | 2122 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 3861 | 0.010 |
Why?
|
|
Diaz-Miron's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|